Published in final edited form as:

Trends Cancer. 2018 May ; 4(5): 385–396. doi:10.1016/j.trecan.2018.03.006.

New Therapies in Head and Neck Cancer

Rodell T. Santuray¹, Daniel E. Johnson², and Jennifer R. Grandis^{2,*}

¹School of Medicine, University of California, San Francisco, CA 94143

²Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco, CA 94143

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a common malignancy with high rates of mortality and morbidity. Beginning with cetuximab, investigators continue to optimize antibody technology to target cell surface receptors that promote HNSCC growth. Small molecules and oligonucleotides have also emerged as therapeutic inhibitors of key receptor-mediated signaling pathways. Although many such therapies have been disappointing in clinical trials as single agents, they continue to be studied in combination with standard therapies. Approvals of pembrolizumab and nivolumab opened a new era of immunotherapy that aims to stimulate anti-tumor immunity in the tumor microenvironment. Immunotherapies are being intensively investigated in new HNSCC clinical trials, with the goal of optimizing the therapeutic potential of this new class of anti-cancer agent.

Keywords

Head; neck; cancer; squamous cell; immunotherapy

Therapeutic Potentials for a Devastating Disease

Head and neck squamous cell carcinoma (HNSCC) is a common epithelial malignancy of the oral cavity, oropharynx, larynx or hypopharynx. Worldwide, HNSCC is the 6th leading cancer and accounts for over 600,000 new cancer cases and 350,000 deaths each year [1,2]. Approximately half of newly diagnosed patients will not survive beyond five years. At diagnosis, 45% of patients already have regional lymph node metastasis. Moreover, the rate of second primary tumor development in HNSCC patients is exceptionally high [3].

In addition to surgery, treatment of HNSCC had long consisted of cytotoxic chemotherapy and radiation. The monoclonal antibody (mAb) platform signaled the beginning of targeted cancer therapy, and in 2006 the anti-EGFR mAb cetuximab was approved for HNSCC. In addition to induction of cytotoxicity, the small molecule paradigm widened to include

*Correspondence: Jennifer.Grandis@ucsf.edu (J.R. Grandis).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

interruption of oncogenic signaling. Further drug approvals in 2016 ushered in a new era of immunotherapy and unleashed the potential for synergistic combination therapies. Table 1 outlines therapies that will be discussed in this review.

Epidermal Growth Factor Receptor

The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases and is abnormally activated in many epithelial cancers, including HNSCC [4]. EGFR activation leads to downstream tumor-promoting activities, and overexpression of EGFR in human tumors correlates with more aggressive disease [5]. Radiation therapy increases EGFR expression; therefore, blockade of signaling emanating from EGFR can sensitize cells to radiation [6,7].

Current Therapies

Cetuximab, a chimeric IgG1 mAb directed against EGFR, was approved in 2006 for use in combination with radiation therapy to treat locally or regionally advanced HNSCC. Findings from a Phase III clinical trial showed statistically significant improvement in locoregional control (24.4 months vs. 14.9 months), median overall survival (OS; 49.0 months vs. 29.3 months), and progression-free survival (PFS) when comparing radiation plus cetuximab to radiation alone [8]. In a single-arm study of patients with platinum-resistant, recurrent or metastatic HNSCC, cetuximab monotherapy showed a response rate of 13% [9]. This led to approval of cetuximab for single-agent use in this population. In 2011, cetuximab in combination with platinum-based therapy plus 5-fluorouracil (5-FU) was approved as first-line treatment for patients with recurrent locoregional and/or metastatic disease. Adding cetuximab to platinum/5-FU therapy prolonged median OS from 7.4 to 10.1 months and prolonged median PFS from 3.3 to 5.6 months [10]. Although these findings indicate a positive benefit of cetuximab treatment, relatively rapid development of resistance is seen in patients with recurrent or metastatic disease. To date, there are no predictive biomarkers for cetuximab response.

In addition to blocking the EGFR pathway and, thereby, inhibiting growth, cetuximab has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) *in vitro* (Figure 1) [11]. Moreover, cetuximab can activate T-cells by increasing dendritic cell cross-presentation [12].

Although the addition of cetuximab to therapeutic regimens represents a significant advance in the treatment of HNSCC, the low response rate to cetuximab monotherapy and eventual treatment failure when combined with other modalities highlight the limitations imposed by high rates of intrinsic and acquired resistance. As described below, other therapies targeting the EGFR pathway are currently under investigation.

Therapies in Development

Panitumumab is a fully human IgG2 mAb that shares an overlapping epitope on EGFR with cetuximab. Like cetuximab, panitumumab also functions to prevent ligand binding [13]. In a Phase III study of patients receiving cisplatin and fluorouracil, the addition of panitumumab was shown to increase PFS, while having no effect on OS [14]. In a Phase II trial of patients

with locally advanced HNSCC, there was no benefit associated with the addition of panitumumab to standard fractionation radiotherapy and cisplatin (CONCERT 1) [15]. Substitution of cisplatin with panitumumab in combined treatment with radiotherapy for unresected stage III-IVb HNSCC resulted in reduced locoregional control (CONCERT-2) [16]. This unremarkable clinical data may be due to panitumumab's inability to induce ADCC, owing to its IgG2 subclass [17]. Like cetuximab, zalutumumab is an IgG1 mAb that can block ligand binding and EGFR dimerization as well as induce ADCC [17,18]. A Phase III study showed that zalutumumab did not increase OS in patients with recurrent or metastatic disease after failure of platinum-based therapy [19]. Unlike the above anti-EGFR mAbs, nimotuzumab blocks ligand binding while still allowing EGFR dimerization and therefore basal activation [20]. Nivolumab is already approved in Cuba for the treatment of advanced, nonoperable HNSCC, and is currently undergoing Phase II testing in conjunction with chemoradiation for locally advanced disease (NCT00702481ⁱ) [21].

In an attempt to mimic the ADCC properties of cetuximab, imgatuzumab was introduced as a glycoengineered mAb for ADCC. The carbohydrate-containing Fc region of this molecule binds avidly to the FcγRIIIa receptor, which is expressed on immune effector cells [22]. In addition to demonstrating clinical activity in *KRAS*-mutated colorectal cancer patients, an exploratory study in HNSCC patients showed that imgatuzumab treatment resulted in increased tumor immune infiltration [23,24]. Sym004 is a mixture of two mAbs that bind to two different epitopes in the extracellular region of EGFR. Sym004 not only blocks ligand binding but also induces internalization and degradation of the receptor. In a trial of patients with cetuximab-resistant HNSCC, nearly half of patients treated with Sym004 experienced a modest tumor response. However, only 12% of Sym004-treated patients were alive without disease progression at 6 months [25,26]. ABBV-221 is an antibody-drug conjugate that utilizes a mAb linked to the antineoplastic agent, monomethyl auristatin E, in order to deliver a toxic payload directly to the tumor site. A Phase I study showed stable disease following ABBV-221 treatment in 38% (16/42) of patients with various EGFR-dependent cancers [27].

Unlike mAbs that are targeted to the extracellular domain of EGFR, a number of small molecule tyrosine kinase inhibitors (TKIs) have been developed that bind to the EGFR intracellular domain and inhibit the intrinsic tyrosine kinase activity (Figure 1). The most studied TKI in HNSCC clinical trials is erlotinib, which binds reversibly. As a single agent in refractory, recurrent and/or metastatic HNSCC, erlotinib has shown only a 4% response rate, which is worse than cytotoxic therapy, and a median survival and 1-year survival comparable to palliative care [28]. In patients with locoregional disease, erlotinib did not increase PFS when added to cisplatin and radiation [29]. An ongoing Phase II study is examining the benefit of adding erlotinib to standard cytotoxic therapy and cetuximab in patients with recurrent or metastatic disease (NCT01316757ⁱⁱ). Another well-studied reversible TKI, gefitinib, did not improve outcomes in recurrent/metastatic disease in a Phase III trial. Dacomitinib is an irreversible TKI that not only targets EGFR (HER1), but also other ErbB family members, including ErbB2 (HER2) and ErbB4 (HER 4). As a single

ⁱ<https://clinicaltrials.gov/ct2/show/NCT00702481>

ⁱⁱ<https://clinicaltrials.gov/ct2/show/NCT01316757>

agent, dacomitinib has shown similar response rates compared to cetuximab in recurrent/metastatic disease [30,31]. Afatinib, an irreversible EGFR and HER2 inhibitor, has shown promise as a second line agent in metastatic disease compared to methotrexate, especially in patients with tumor biomarkers: p16-negative, EGFR-amplified, HER3-low, and PTEN-high [32].

Phosphoinositide 3-kinase/Mechanistic Target of Rapamycin

Once activated, receptor tyrosine kinases initiate several signal transduction cascades, including activation of the phosphoinositide 3-kinase (PI3K) pathway. PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP₂) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP₃), which in turn activates PDK1 and AKT (Figure 1). Activated AKT phosphorylates the mechanistic target of rapamycin (mTOR), leading to cell cycle progression, proliferation, and cell survival. Aberrant hyperactivation of the PI3K pathway has been observed in half of HNSCC cases. The PI3K enzyme is comprised of multiple catalytic and regulatory isoforms, but mutations in *PIK3CA*, the gene encoding p110 α catalytic subunit, have been detected in 35% of HNSCC tumors [33]. *In vivo* studies have shown that patient-derived xenograft tumors harboring these mutations are sensitive to a PI3K inhibitor, suggesting opportunities for future clinical investigations [34]. Downstream of PI3K, mTOR has been shown to be activated in >70% of HNSCC specimens and therefore presents another favorable target for therapy [35].

Therapies in Development

When added to paclitaxel, the pan-PI3K inhibitor, buparlisib, demonstrated increased PFS in patients with platinum-pretreated recurrent/metastatic HNSCC [36]. Buparlisib is also being studied in combination with cetuximab in recurrent/metastatic disease and as monotherapy in patients with platinum- and cetuximab-refractory disease (NCT01816984ⁱⁱⁱ, NCT01737450^{iv}). To increase delivery to target sites, the pan-PI3K inhibitor SF1126 includes a peptide sequence that binds to integrins ($\alpha v\beta 3/\alpha 5\beta 1$) expressed on the surface of endothelial and tumor cells [37]. Also in clinical trials are the isoform-specific PI3K inhibitors, alpelisib (anti-p110 α), INCB050465 (anti-p110 δ), and copanlisib (anti-p110 α and anti-p110 δ), which have been developed in an attempt to minimize the adverse effects observed with less specific inhibitors (NCT02145312^v, NCT02822482^{vi}). Another isoform, p110 γ , is the target of IPI-549. Unlike the above-mentioned targets, the p110 γ isoform is highly expressed in myeloid cells. p110 γ inhibition switches activation of macrophages from the immunosuppressive M2 subtype to the proinflammatory M1 subtype [38]. Therefore, IPI-549 has the potential to work synergistically with established immunotherapies to overcome resistance.

Everolimus and temsirolimus are mTOR inhibitors that are also being studied to disrupt PI3K pathway signaling. Everolimus as monotherapy did not show clinical activity in

ⁱⁱⁱ<https://clinicaltrials.gov/ct2/show/NCT01816984>

^{iv}<https://clinicaltrials.gov/ct2/show/NCT01737450>

^v<https://clinicaltrials.gov/ct2/show/NCT02145312>

^{vi}<https://clinicaltrials.gov/ct2/show/NCT02822482>

patients with recurrent/metastatic disease nor did everolimus with erlotinib produce a significant benefit for patients with platinum-resistant disease [39,40]. Everolimus is currently being studied in induction and adjuvant therapy in locally advanced disease (NCT01133678^{vii}, NCT01111058^{viii}). Temsirolimus in combination with carboplatin and paclitaxel in patients with recurrent/metastatic disease resulted in a 41.7% objective response [41].

The modest clinical effects of PI3K/mTOR inhibitor monotherapy may be due to feedback activation of several receptor tyrosine kinases [42]. Combination therapy and pre-selection of patients with relevant PI3K/mTOR mutations may maximize the efficacy of these inhibitors [43].

Signal Transducer and Activator of Transcription

The ultimate target site of most signal transduction cascades is gene expression in the nucleus, where transcription factors can drive oncogenic signaling. The signal transducer and activator of transcription (STAT) family of proteins mediate various cellular functions related to oncogenesis (Figure 1). Increased activation of STAT3 in particular has been observed in many cancers and is a well-validated target for therapeutics [44]. Activation of STAT3 is associated with negative prognoses in many malignancies including colorectal, cervical, and gastric cancers [45–47]. Unlike enzymatic targets (egg. kinases), however, transcription factors like STAT3 lack the catalytic pockets amenable to small-molecule inhibition. Moreover, their intracellular localization makes them difficult to target with mAbs.

Therapies in Development

By harnessing the DNA binding activity of STAT3, an oligonucleotide “decoy” inhibitor was developed. This decoy consists of a 15-bp double-stranded oligonucleotide that is derived from a STAT3 response element in the *c-fos* promoter. The STAT3 decoy competitively inhibits STAT3 binding to genomic DNA and inhibits target gene expression in preclinical models [48]. In the first clinical trial involving a STAT3-specific inhibitor, the decoy was injected into patient tumors prior to resection. Compared to tumors injected with saline, specimens from decoy-injected tumors showed reduced expression of the STAT3 target genes encoding cyclin D1 and Bcl-X_L. Subsequent cyclization of the decoy molecule has allowed for effective systemic administration and anti-tumor activity in preclinical models [49]. Only one small molecule STAT3 inhibitor, C188-9, is currently being evaluated in clinical trials (NCT03195699^{ix}). C188-9 targets a peptide-binding site within the STAT3 Src homology 2 (SH2) domain, which is necessary for dimerization and activation of STAT3 [50].

Another approach being used to downregulate STAT3 signaling in cancer cells involves the use of antisense. AZD9150 is a STAT3 antisense oligonucleotide that has been shown to

^{vii}<https://clinicaltrials.gov/ct2/show/NCT01133678>

^{viii}<https://clinicaltrials.gov/ct2/show/NCT01111058>

^{ix}<https://clinicaltrials.gov/ct2/show/NCT03195699>

decrease STAT3 mRNA and protein levels and inhibit the growth of xenograft tumors in preclinical models. A Phase I clinical trial of AZD9150 showed antitumor activity in patients with treatment-refractory lymphoma and non-small cell lung cancer. These results have led to an ongoing Phase II trial of AZD9150 in advanced solid tumors including HNSCC (NCT02499328^x) [51].

Immunotherapy

The immunotherapeutic landscape for HNSCC encompasses a variety of targets that suppress or stimulate the immune system's ability to eliminate neoplastic cells. Activation of checkpoint receptors, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein (CTLA-4), causes T cell suppression. In contrast, activation of co-stimulatory receptors, such as CD40, glucocorticoid-induced tumor necrosis factor receptor (GITR), and toll-like receptors (TLRs), causes immune system stimulation. In addition to receptor signaling, certain enzymes, such as indoleamine 2,3-dioxygenase (IDO) and arginase 1 (Arg1), modify the tumor microenvironment by depleting nutrients essential for T cell proliferation while other enzymes, such as inducible nitric oxide synthase (NOS2), produce toxins that inhibit T cell proliferation.

A functioning immune system with the capacity to eliminate neoplastic cells is dependent on T cell recognition of antigens along with co-stimulatory and inhibitory signals. Co-stimulatory signals contribute to the defense against pathogens while inhibitory signals prevent autoimmunity. Cancer cells have been shown to express ligands that lead to inhibitory signaling in order to evade elimination by T cells [52]. These ligands bind to receptors, often called checkpoint receptor proteins, on the surface of T cells, resulting in T cell suppression (Figure 2). One such inhibitory receptor is PD-1, which is expressed on activated T cells. PD-1 expression and engagement has been shown to inhibit immune-modulated tissue damage as well as lead to suppression of T cell proliferation during chronic infections [53]. The expression of checkpoint ligands such as PD-L1 and PD-L2 by tumors leads to evasion of the anti-tumor immune response. Efforts to prevent this mechanism of immune evasion have led to the development and approval of the two newest therapies for HNSCC. Combinations of immune and antineoplastic therapies are being studied to maximize immunostimulatory effects.

Current Therapies

Pembrolizumab is a mAb directed against PD-1 and was first approved for use in metastatic melanoma. In August 2016, it was granted accelerated approval as a single agent in patients with recurrent/metastatic HNSCC with disease progression on or after platinum chemotherapy. Approval was based on the results of a Phase Ib trial that showed an overall response rate of 18% in this population. Moreover, median duration of response (time from initial disease response to disease progression) for pembrolizumab was 53 weeks compared to 4 months for cetuximab [54]. A Phase III study comparing pembrolizumab with standard of care (SOC) in patients with recurrent or platinum-resistant disease showed an increase in

^x<https://clinicaltrials.gov/ct2/show/NCT02499328>

OS from 7.1 months in the SOC group to 8.4 in the pembrolizumab group. This result of unstratified data was not statistically significant but alluded to the presence of prolonged stable disease. In fact, in patients harboring tumors with PD-L1 expression in >50% of their cancer cells, OS improved to 11.6 in the pembrolizumab group vs. 7.9 months in the SOC group [55].

This study also suggests that pembrolizumab may be a better treatment option in this population due to its favorable toxicity profile compared to SOC. In addition, results from a study of patients with recurrent/metastatic disease refractory to both platinum and cetuximab show an overall response rate of 16% [56]. An ongoing Phase III study in patients with recurrent/metastatic HNSCC is evaluating pembrolizumab alone or in combination with cisplatin and 5-FU versus cetuximab in combination with cisplatin and 5-FU (NCT02358031^{xi}).

Nivolumab is another mAb targeting PD-1 and was approved in November 2016 for use as a single agent in patients with recurrent/metastatic HNSCC with disease progression on or after platinum chemotherapy. This approval was based on results from a Phase III study comparing nivolumab to standard, single-agent therapies of methotrexate, docetaxel, or cetuximab. Compared to standard therapy, nivolumab showed improvement in median OS from 5.1 months to 7.5 months and an increase in the estimated 1-year survival rate from 16.6% to 36.0%. In addition, the response rate in the nivolumab group was 13.3% compared to 5.8% in the standard therapy group [57].

Although the response rates of pembrolizumab and nivolumab in HNSCC remain below 20%, the dramatic improvements in OS compared to SOC suggest prolonged stable disease. Checkpoint inhibition offers tremendous promise, and there is a high level of interest in this therapeutic approach. Pembrolizumab and nivolumab are involved in 47 and 25 active clinical trials, respectively. In addition to being studied in the neoadjuvant setting and in combination with radiotherapy, PD-1 inhibitors are being studied with other chemotherapeutic modalities in hopes of maximizing the potential of immunotherapy.

Therapies in Development

Like PD-1, CTLA-4 is also a checkpoint receptor protein that inhibits T cell activation (Figure 2). T cell inhibition mediated by PD-1 and CTLA-4, however, occurs via distinct intracellular mechanisms [58]. In addition, CTLA-4 can cause further immunosuppression via its constitutive expression on regulatory T cells (Tregs), which results in competitive binding to B7. The co-inhibitory CTLA-4 receptor is a homologue of the co-stimulatory CD28 receptor, and both bind the B7 ligand. The binding of B7 to CTLA-4 is thought to down-regulate cell surface expression of B7 on antigen presenting cells, leading to reduced CD28-B7 co-stimulation [59]. In a HNSCC patient cohort, CTLA-4-positive Tregs were enriched in tumor infiltrating lymphocytes and were the suspected cause of the observed dysfunction of the neighboring effector cells [60]. Moreover, in a study of cetuximab-treated HNSCC patients, those with increased frequency of circulating CTLA-4 had worse clinical outcomes [61]. Ipilimumab is a mAb directed against CTLA-4 and is approved for treatment

^{xi}<https://clinicaltrials.gov/ct2/show/NCT02358031>

of metastatic melanoma. Ipilimumab is undergoing trials both as a single-agent and in combination with nivolumab in recurrent/metastatic HNSCC. The differing mechanisms of action of CTLA-4 and PD-1 offer potential for synergistic activity. A Phase III study in untreated metastatic melanoma showed improved PFS with the combination of nivolumab and ipilimumab versus treatment with either agent alone [62].

In contrast to antagonizing co-inhibitory receptors, other therapeutic approaches seek to stimulate co-stimulatory proteins. CD40 is a co-stimulatory receptor expressed on antigen-presenting cells (APCs) and binds to its ligand on activated T cells in order to initiate adaptive immunity (Figure 2). SEA-CD40 is a mAb that promotes APC maturation, up-regulation of co-stimulatory receptors, and production of pro-inflammatory cytokines *in vitro*. Moreover, like imtazumab described above, SEA-CD40 is also designed to bind to Fc γ RIIIa with high affinity in order to induce ADCC [63]. SEA-CD40 is currently being evaluated in a Phase I trial as monotherapy and in combination with pembrolizumab in HNSCC (NCT02376699^{xii}). ABBV-927 is another agonistic mAb directed against CD40 and is in Phase I trials as monotherapy and in combination with nivolumab (NCT02988960^{xiii}).

GITR is another co-stimulatory protein that can be targeted to promote antitumor immune response (Figure 2). In mouse models, GITR co-stimulation led to proliferation of CD8⁺ and CD4⁺ peripheral T cell populations. Treg proliferation was also triggered, but with a corresponding loss of the anergic phenotype [64]. INCAGN01876 is an agonistic mAb directed against GITR and is undergoing Phase I trials in combination with pembrolizumab and nivolumab in patients with various metastatic cancers, including HNSCC (NCT03126110^{xiv}).

Like CD40 and GITR, TLRs can also be targeted with agonists (Figure 2). Part of the innate immune system, TLRs recognize conserved microbial products, such as bacterial lipopolysaccharides, and transduce signals that lead to host defense [65]. SD-101 is a novel oligonucleotide therapeutic agent that binds to TLR9. Intratumoral injection of SD-101 in combination with pembrolizumab is being studied in patients with recurrent/metastatic HNSCC (NCT02521870^{xv}). The small molecule TLR8 agonist, motolimod, is being studied in the neoadjuvant setting in combination with cetuximab and nivolumab in patients with resectable tumors (NCT02124850^{xvi}).

In addition to receptor targeting, modification of the tumor microenvironment can also be exploited to promote antitumor immune responses (Figure 2). IDO catalyzes the initial rate-limiting step in tryptophan catabolism, and IDO expression in various tumor types correlates with poor prognoses [66–68]. Tryptophan-deficient conditions lead to T cell cycle arrest *in vitro*, and IDO inhibition exhibits antitumor effects *in vivo*, suggesting a role for IDO in tumor immune escape [69,70]. The small molecule IDO inhibitor, epacadostat, is being

^{xii}<https://clinicaltrials.gov/ct2/show/NCT02376699>

^{xiii}<https://clinicaltrials.gov/ct2/show/NCT02988960>

^{xiv}<https://clinicaltrials.gov/ct2/show/NCT03126110>

^{xv}<https://clinicaltrials.gov/ct2/show/NCT02521870>

^{xvi}<https://clinicaltrials.gov/ct2/show/NCT02124850>

investigated in combination with pembrolizumab in the neoadjuvant setting in patients with resectable HNSCC and with nivolumab in advanced HNSCC (NCT03325465^{xvii}, NCT02327078^{xviii}).

Another approach for modifying the tumor microenvironment involves interfering with the function of myeloid-derived suppressor cells (MDSCs). MDSCs exert their immunomodulating effects through diverse mechanisms, including Arg1-mediated depletion of L-arginine and production of nitric oxide (NO) via NOS2 [71]. Similar to the effects of IDO on local tryptophan concentrations, Arg1 acts to starve the tumor microenvironment of L-arginine, thus limiting T cell proliferation. INCB001158 is a small molecule arginase inhibitor that is being studied in clinical trials both as monotherapy and in combination with pembrolizumab (NCT02903914^{xix}). In addition to L-arginine depletion, NO production also transforms the tumor microenvironment to promote immune escape. Short-term NO exposure reversibly inhibits T cells, and sustained exposure leads to T cell apoptosis [72]. L-NMMA is a small molecule pan nitric oxide synthase inhibitor that is being investigated in combination with pembrolizumab (NCT03236935^{xx}). Interestingly, inhibition of phosphodiesterase 5 (PDE5) leads to increased cGMP within MSDCs, resulting in reduced expression of Arg1 and NOS2 [73]. Treatment of HNSCC patients with the PDE5 inhibitor tadalafil led to decreased circulating and tumor MSDCs and Tregs, and elevated levels of circulating CD8⁺ T cells [74]. Tadalafil is currently being studied in combination with nivolumab (NCT03238365^{xxi}).

Concluding Remarks

Targeted therapy in HNSCC began with molecules directed against the extracellular region of EGFR, evolved to interrupt downstream components of receptor-mediated intracellular signaling, and now involves activation of anti-tumor immunity. Existing targets will continue to be pursued using new technology platforms like antibody-drug conjugates and oligonucleotides (see Outstanding Questions). In addition to systemic administration of emerging therapies, there is also potential for their use in the perioperative setting to decrease tumor burden and in combination with radiation to promote chemosensitization. Because of the vast number of therapies being studied, reliable biomarkers should be developed to identify patients most likely to benefit. In metastatic non-small cell lung cancer (NSCLC), for example, testing for PD-L1 expression guides first-line treatment of TKIs versus pembrolizumab. The potential of combination regimens using emerging therapies is both promising and resource-prohibitive. In view of the large number of potential combinations to be tested, prioritization criteria should be established to yield the most effective treatments in a timely manner. In addition to target identification, the next decade in HNSCC therapy research is poised to focus on new drug technology platform development, utilization of other treatment modalities, and optimization of combination regimens. Realization of this research, along with the results of ongoing clinical trials, is

^{xvii}<https://clinicaltrials.gov/ct2/show/NCT03325465>

^{xviii}: <https://clinicaltrials.gov/ct2/show/NCT02327078>

^{xix}<https://clinicaltrials.gov/ct2/show/NCT02903914>

^{xx}<https://clinicaltrials.gov/ct2/show/NCT03236935>

^{xxi}<https://clinicaltrials.gov/ct2/show/NCT03238365>

critical to moving beyond incremental improvement of patient prognoses and achieving curative results in this devastating disease.

References

1. Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of Cancer*. 2010; 127:2893–2917. [PubMed: 21351269]
2. Fitzmaurice C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncology*. 2017; 3:524–548. [PubMed: 27918777]
3. Schöder H. Head and Neck Cancer. In: Strauss HW, , et al., editors *Nuclear Oncology: Pathophysiology and Clinical Applications*. Springer; New York: 2013. 269–295.
4. Salomon DS, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. *Critical Reviews in Oncology and Hematology*. 1995; 19:183–232.
5. Baselga J, Mendelsohn J. Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer. *Journal of Clinical Oncology*. 2003; 21:2787–2799. [PubMed: 12860957]
6. Bonner JA, et al. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. *International Journal of Radiation Oncology, Biology, Physics*. 1994; 29:243–247.
7. Liang K, et al. The epidermal growth factor receptor mediates radioresistance. *International Journal of Radiation Oncology, Biology, Physics*. 2003; 57:246–254.
8. Bonner JA, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. *The New England Journal of Medicine*. 2006; 354:567–578. [PubMed: 16467544]
9. Vermorken Jan B, , et al. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy. *Journal of Clinical Oncology*. 2007; 25:2171–2177. [PubMed: 17538161]
10. Vermorken JB, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. *The New England Journal of Medicine*. 2008; 359:1116–1127. [PubMed: 18784101]
11. Kimura H, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. *Cancer Science*. 2007; 98:1275–1280. [PubMed: 17498200]
12. Yang X, et al. Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses. *Molecular Therapy*. 2013; 21:91–100. [PubMed: 22990672]
13. Voigt M, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. *Neoplasia*. 2012; 14:1023–1031. [PubMed: 23226096]
14. Vermorken JB, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. *Lancet Oncology*. 2013; 14:697–710. [PubMed: 23746666]
15. Mesía R, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. *Lancet Oncology*. 2015; 16:208–220. [PubMed: 25596660]
16. Giralt Jordi, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. *Lancet Oncology*. 2015; 16:221–232. [PubMed: 25596659]
17. Rivera F, et al. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. *Acta Oncologica*. 2008; 47:9–19. [PubMed: 18097777]
18. Lammerts van Bueren JJ, et al. The Antibody Zalutumumab Inhibits Epidermal Growth Factor Receptor Signaling by Limiting Intra- and Intermolecular Flexibility. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:6109–6114. [PubMed: 18427122]

19. Machiels J, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. *Lancet Oncology*. 2011; 12:333–343. [PubMed: 21377930]
20. Talavera A, et al. Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation. *Cancer Research*. 2009; 69:5851–5859. [PubMed: 19584289]
21. Reddy BKM, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. *Oral Oncology*. 2014; 50:498. [PubMed: 24613543]
22. Gerdes CA, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*. 2013; 19:1126–1138. [PubMed: 23209031]
23. Delord J, et al. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. *European Journal of Cancer*. 2014; 50:496–505. [PubMed: 24262587]
24. Temam S, et al. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma. *Annals of Oncology*. 2017; 28:2827–2835. [PubMed: 28950289]
25. Pedersen MW, et al. Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy. *Cancer Research*. 2010; 70:588–597. [PubMed: 20068188]
26. Machiels J, et al. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. *Cancer Chemother Pharmacol*. 2015; 76:13–20. [PubMed: 25952795]
27. Calvo E, et al. Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR. *Jco*. 2017; 35:2510.
28. Soulieres D, et al. Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck. *Journal of Clinical Oncology*. 2004; 22:77–85. [PubMed: 14701768]
29. Martins RG, et al. Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. *Journal of Clinical Oncology*. 2013; 31:1415–1421. [PubMed: 23460709]
30. Abdul Razak AR, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*. 2013; 24:761–769. [PubMed: 23108949]
31. Han SK, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*. 2015; 21:544–552. [PubMed: 25424851]
32. Cohen EEW, et al. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. *Annals of Oncology*. 2017; 28:2526–2532. [PubMed: 28961833]
33. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*. 2015; 517:576–582. [PubMed: 25631445]
34. Lui VWY, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. *Cancer Discovery*. 2013; 3:761. [PubMed: 23619167]
35. García-Carracedo D, et al. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. *Oncotarget*. 2016; 7:29780. [PubMed: 27119232]

36. Soulières D, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Oncology*. 2017; 18:323–335. [PubMed: 28131786]
37. Garlich JR, et al. A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity. *Cancer Research*. 2008; 68:206–215. [PubMed: 18172313]
38. De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K γ in myeloid cells. *Nature*. 2016; 539:443–447. [PubMed: 27828943]
39. Geiger JL, et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. *Head & Neck*. 2016; 38:1759–1764. [PubMed: 27232378]
40. Massarelli E, et al. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*. 2015; 26:1476–1480. [PubMed: 26025965]
41. Dunn LA, et al. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). *Annals of Oncology: Official Journal of the European Society for Medical Oncology*. 2017; 28:2533–2538. [PubMed: 28961834]
42. Garrett JT, et al. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? *Oncotarget*. 2011; 2:1314. [PubMed: 22248929]
43. Massacesi C, et al. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. *OncoTargets and Therapy*. 2016; 9:203–210. [PubMed: 26793003]
44. Hodge DR, et al. The role of IL-6 and STAT3 in inflammation and cancer. *European Journal of Cancer*. 2005; 41:2502–2512. [PubMed: 16199153]
45. Kusaba T, et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. *Oncology Reports*. 2006; 15:1445. [PubMed: 16685378]
46. Takemoto S, et al. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. *British Journal of Cancer*. 2009; 101:967–972. [PubMed: 19638983]
47. Kim D, et al. STAT3 expression in gastric cancer indicates a poor prognosis. *J Gastroenterol Hepatol*. 2009; 24:646–651. [PubMed: 19175826]
48. Leong PL, et al. Targeted Inhibition of Stat3 with a Decoy Oligonucleotide Abrogates Head and Neck Cancer Cell Growth. *Proceedings of the National Academy of Sciences of the United States of America*. 2003; 100:4138–4143. [PubMed: 12640143]
49. Sen M, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. *Cancer Discovery*. 2012; 2:694–705. [PubMed: 22719020]
50. Redell MS, et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. *Blood*. 2011; 117:5701–5709. [PubMed: 21447830]
51. Hong D, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. *Science Translational Medicine*. 2015; 7:314ra185.
52. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nature Reviews: Cancer*. 2012; 12:252–264. [PubMed: 22437870]
53. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. *Cancer Medicine*. 2013; 2:662–673. [PubMed: 24403232]
54. Seiwert TY, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. *Lancet Oncology*. 2016; 17:956–965. [PubMed: 27247226]
55. Cohen EE, et al. Paper presented at ESMO 2017 Congress; Madrid, Spain. Madrid, Spain: Sep 11, 2017
56. Bauml J, et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. *Jco*. 2017; 35:1542–1549.

57. Ferris RL, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *The New England Journal of Medicine*. 2016; 375:1856. [PubMed: 27718784]
58. Parry RV, et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. *Molecular and Cellular Biology*. 2005; 25:9543–9553. [PubMed: 16227604]
59. Qureshi OS, et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. *Science*. 2011; 332:600–603. [PubMed: 21474713]
60. Albers AE, et al. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. *Cancer Immunology, Immunotherapy*. 2005; 54:1072–1081. [PubMed: 15959774]
61. Jie H, et al. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. *Cancer Research*. 2015; 75:2200–2210. [PubMed: 25832655]
62. Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015; 373:23–34. [PubMed: 26027431]
63. Gardai SJ, et al. A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors. *Jco*. 2015; 33:3074.
64. Ronchetti S, et al. Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. *Eur J Immunol*. 2004; 34:613–622. [PubMed: 14991590]
65. Medzhitov R. Toll-like receptors and innate immunity. *Nature Reviews Immunology*. 2001; 1:135.
66. Brandacher G, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. *Clinical Cancer Research*. 2006; 12:1144–1151. [PubMed: 16489067]
67. Okamoto A, et al. Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells. *Clinical Cancer Research*. 2005; 11:6030–6039. [PubMed: 16115948]
68. Ino K, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. *British Journal of Cancer*. 2006; 95:1555–1561. [PubMed: 17117179]
69. Munn DH, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. *The Journal of Experimental Medicine*. 1999; 189:1363–1372. [PubMed: 10224276]
70. Sutanto-Ward E, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. *Nature Medicine*. 2005; 11:312–319.
71. Ostrand-Rosenberg S, Sinha P. Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. *The Journal of Immunology*. 2009; 182:4499. [PubMed: 19342621]
72. Bronte V, et al. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. *Trends in Immunology*. 2003; 24:301–305.
73. Serafini P, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. *Journal of Experimental Medicine*. 2006; 203:2691–2702. [PubMed: 17101732]
74. Weed DT, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*. 2015; 21:39–48. [PubMed: 25320361]

Highlights

- Prior to cetuximab approval in 2006, treatment for head and neck cancer consisted of cytotoxic chemotherapy and radiation.
- Patients with recurrent and metastatic disease rapidly develop resistance to cetuximab, so novel EGFR-targeting therapies, such as antibody drug conjugates and glycoengineered immunostimulatory mAbs, are being studied.
- Small molecules and oligonucleotides are being developed to inhibit the downstream components of receptor signaling cascades including intracellular tyrosine kinases, PI3K, and STAT3.
- Approval of pembrolizumab and nivolumab in 2016 ushered in a new era of immunotherapy for HNSCC and unleashed the potential for synergistic combination therapies.
- Immunotherapeutic strategies include promotion of immunostimulatory signaling and inhibition of immunosuppressive signaling.

- With the vast number of therapies in development, can biomarkers be developed to guide targeted treatment in head and neck cancer, as is the case with PD-L1 expression in NSCLC?
- Is there a way to prioritize combination regimens in clinical trials, particularly those incorporating immunotherapy?
- Can targeted therapies be optimized with other modalities like radiation and surgery?
- Are there expanded opportunities for novel therapeutic agents such as oligonucleotides? Can they be developed for safe and effective systemic administration?

Figure 1. Stimulation of the EGFR Pathway Drives Survival and Proliferation of Tumor Cells

The epidermal growth factor receptor (EGFR) transduces extracellular signals by activating phosphoinositide 3-kinase (PI3K), which in turn facilitates the conversion of phosphatidylinositol 4,5-bisphosphate (PIP₂) to phosphatidylinositol 3,4,5-trisphosphate (PIP₃). Presence of PIP₃ ultimately results in cell survival and proliferation via several downstream mediators, notably the mechanistic target of rapamycin (mTOR). EGFR can also activate the signal transducer and activator of transcription 3 (STAT3), which is a transcription factor for genes involved in cell survival and proliferation. Monoclonal antibody-based therapeutics include cetuximab, panitumumab, nimotuzumab, zalutumumab, Sym004, ABBV-221, and imgatuzumab, which all target the EGFR extracellular domain. Erlotinib, gefitinib, dacomitinib, and afatinib are small molecule tyrosine kinase inhibitors that are directed toward the EGFR intracellular domain. PI3K is targeted by small molecules that include buparlisib, SF1126, alpelisib, INCB050465, copanlisib, and IPI-549. Sirolimus, everolimus, and temsirolimus are related compounds that inhibit mTOR. In addition to small molecule inhibition, therapeutic oligonucleotide decoys can bind to STAT3, and antisense oligonucleotides like AZD9150 can silence STAT3 mRNA.

Figure 2. Immunotherapy Landscape in Head and Neck Cancer

Binding of programmed cell death protein 1 (PD-1) to its ligand, PD-L, causes T cell suppression. Pembrolizumab and nivolumab are mAbs that bind to PD-1 and antagonize its immunosuppressive effects. Activation of cytotoxic T-lymphocyte-associated protein (CTLA-4) also causes T cell suppression. Moreover, binding of CTLA-4 to B7 causes B7 downregulation, which is also immunosuppressive. Ipilimumab prevents ligand binding to CTLA-4, thereby antagonizing this immunosuppression. Activation of co-stimulatory receptors, such as CD40, glucocorticoid-induced tumor necrosis factor receptor (GITR), and toll-like receptors (TLRs), causes immune system stimulation. Binding of mAb SEA-CD40 to CD40 causes antigen presenting cell (APC) maturation and can also induce antibody-dependent cell-mediated cytotoxicity (ADCC) by binding the Fc γ RIII α receptor. The mAb INCAGN01876 binds GITR and ultimately leads to T cell proliferation. The small molecule motolimod, and oligonucleotide SD-101 bind TLRs on APCs, thereby stimulating host defense. Indoleamine 2,3-dioxygenase (IDO) and arginase 1 (Arg1) deplete tryptophan and L-arginine, respectively. Both amino acids are essential for T cell proliferation. Epacadostat inhibits IDO while INCB001158 inhibits Arg1. Inducible nitric oxide synthase (NOS2) produces nitric oxide (NO), which causes T cell suppression. L-NMMA is a NOS2 inhibitor.

Table 1

Therapies in Development for Head and Neck Cancer

Target	Name	Class
Epidermal growth factor receptor (EGFR), extracellular	Cetuximab	Monoclonal antibody
	Panitumumab	
	Nimotuzumab	
	Zalutumumab	
	Sym004	
	ABBV-221	
Epidermal growth factor receptor (EGFR), tyrosine kinase	Erlotinib	Small molecule
	Gefitinib	
	Dacomitinib	
	Afatinib	
Phosphoinositide 3-kinase (PI3K)	Buparlisib	Small molecule
	SF1126	
	Alpelisib	
	INCB050465	
	Copanlisib	
	IPI-549	
Mechanistic target of rapamycin (mTOR)	Sirolimus	Small molecule
	Everolimus	
	Temsirolimus	
Signal transducer and activator of transcription 3 (STAT3)	C188-9	Small molecule
	Decoy	Oligonucleotide
	AZD9150	
Programmed cell death protein 1 (PD-1)	Pembrolizumab	Monoclonal antibody
	Nivolumab	
Cytotoxic T-lymphocyte-associated protein (CTLA-4)	Ipilimumab	
CD40	SEA-CD40	
Glucocorticoid-induced tumor necrosis factor receptor (GITR)	INCAGN01876	
Toll-like receptor (TLR)	Motolimod	Small molecule
	SD-101	Oligonucleotide
Indoleamine 2,3-dioxygenase (IDO)	Epacadostat	Small molecule
Arginase 1 (Arg1)	INCB001158	
Inducible nitric oxide synthase (NOS2)	L-NMMA	